Posted by Nikola > 2021-02-01 23:51 | Report Abuse

Please credit the Reddit writer. It’s good practise to do so, while everything is self regulatory.

Posted by pBlue > 2021-02-01 23:58 | Report Abuse

Using the name of an entire reddit community as your name isn't cool. Show some netiquette.

Posted by Hazzyy > 2021-02-02 01:43 | Report Abuse

Too complicated . Is there a simpler way to explain. Turning left right up and down I tak faham. Follow Uncle Koon lah, from FA to TA to FA . What is yours TFA ?

Posted by Addy > 2021-02-02 08:40 | Report Abuse

Gov’t deal with Pfizer
https://www.youtube.com/watch?v=lUIVkuGcSfo

Posted by Addy > 2021-02-02 08:40 | Report Abuse

Malaysia has signed a COVID-19 vaccine deal with AstraZeneca. It has secured 6.4 million doses, on top of an agreement with Pfizer-BioNTech for nearly 13 million doses.
https://www.youtube.com/watch?v=ohueRwZU4vY

Posted by Addy > 2021-02-02 08:40 | Report Abuse

Malaysia orders 14 million China-developed COVID-19 vaccine doses
https://www.youtube.com/watch?v=1rmkHJ2f3KY

Posted by Addy > 2021-02-02 08:40 | Report Abuse

Covid Vaccine
Astra Zeneca (UK)
price :US$ 4 per dose
dosed required :2

sinovac (CHINA)
price :US$ 5 per dose
dosed required :2

moderna (USA)
price :US$ 33per dose
dosed required :2

pfizer biontech (USA GERMANY)
price :US$ 20per dose
dosed required :2

Sputnik (RUSSIA)
price :US$ 10per dose
dosed required :2

johnson johnson (USA)
price :US$ 10per dose
dosed required :1

Posted by Addy > 2021-02-02 08:41 | Report Abuse

President-elect Joe Biden gets first dose of Covid-19 vaccine
https://www.youtube.com/watch?v=VHCQ3cM02DQ

Posted by Addy > 2021-02-02 08:41 | Report Abuse

Indonesian president Jokowi receives Covid-19 jab, starting vaccination
https://www.youtube.com/watch?v=ZMVAcPMCMGc

Posted by Addy > 2021-02-02 08:41 | Report Abuse

Singapore PM Lee Hsien Loong receives first dose of Pfizer-BioNTech vaccine
https://www.youtube.com/watch?v=XSb7WB8SStw

Posted by Addy > 2021-02-02 08:42 | Report Abuse

Israeli PM Benjamin Netanyahu Receives Pfizer Vaccine
https://www.youtube.com/watch?v=QUmaw2kERdg

Posted by Addy > 2021-02-02 08:42 | Report Abuse

Kamala Harris receives Covid-19 vaccine: 'That was easy'
https://www.youtube.com/watch?v=X4itlOyqHyI

Posted by Addy > 2021-02-02 08:42 | Report Abuse

President-elect Biden receives his second dose of coronavirus vaccine
https://www.youtube.com/watch?v=IU_dV6VOn1k

Posted by Addy > 2021-02-02 08:42 | Report Abuse

https://www.theedgemarkets.com/content/evening-5-184-million-covid19-v...
18.4 million Covid-19 vaccine doses incoming
In today’s edition of Evening 5, Pharmaniaga and Duopharma Biotech have signed two separate Covid-19 vaccine deals that will cumulatively bring 18.4 million doses to the people.

Posted by Addy > 2021-02-02 08:43 | Report Abuse

华尔街大鳄惨败YOLO股民 马股能重复奇迹?
https://www.youtube.com/watch?v=pyd_pOGULxk&fbclid=IwAR1A6QHBcuQF6

Posted by Mat Cendana > 2021-02-02 19:46 | Report Abuse

"Those with the knowledge would have bought glove counters and held on to it when Covid was announced in China. Many did not." <--- I'm one of those who failed to get onboard at the ground floor.

Gloves were such `an obvious play' that I missed it! It had felt `too obvious' and resulted in over-analysing.

Posted by sensonic > 2021-02-02 20:02 | Report Abuse

KUALA LUMPUR (Feb 2): RHB Research Institute and Kenanga Research have trimmed their target prices (TPs) for Supermax Corp Bhd due to a lack of visibility of its average selling prices (ASPs) and execution risk of its US venture.

Kenanga Research analyst Raymond Choo Ping Khoon, who kept his "outperform" call, said the research house had cut its TP to RM9.05 from RM7.80 previously based on 12 times calendar year 2022 estimated (CY22E) earnings per share (EPS) as the research house rolled over its valuation base from CY21 to CY22.

This was due to execution risk of the company's US venture to manufacture medical gloves and other personal protective equipment (PPE) with an initial capital outlay of RM405 million, as well as the lack of ASP visibility, he noted.

Supermax previously noted that while ASPs had not peaked in the first quarter of 2021 (1Q21) yet, demand is expected to moderate with the roll-out of Covid-19 vaccines.

As at the time of writing today, shares of Supermax had risen seven sen or 1.03% to RM6.87, valuing the group at RM18.69 billion. It had seen some 15.97 million shares traded.

Meanwhile, RHB Research Institute, which maintained its "buy" call on Supermax, lowered its TP to RM10.60 (from RM13.25), with a 56% upside and an about 7% yield.

“Our TP reflects 8.3 times FY22F P/E (price-earnings forecast for the financial year ending June 30, 2022; a 20% discount versus peers). This discount is justified due to Supermax’s lower market capitalisation. Our ‘buy’ call is premised on stronger earnings prospects for 3QFY21 (the third quarter ending March 31, 2021), an expected positive news flow from its venture to build a manufacturing plant in the US and its dual listing on the Singapore Exchange (SGX).

“We lower our TP to RM10.60. [Our] long-term ASP [assumptions] have been lowered to US$47 (RM190.04)/box (from US$48) as higher near-term ASPs should result in stronger competition in the long run. Beta has been increased to account for higher share price volatility,” said RHB analyst Alan Lim.

To recap, the glove maker’s net profit for the latest quarter, 2QFY21, climbed 34% quarter-on-quarter (q-o-q) to RM1.06 billion from RM789.52 million for the preceding 1QFY21, while quarterly revenue surged to RM2 billion compared with RM1.35 billion for the preceding quarter.

On a yearly basis, net profit jumped by a whopping 3,142% from RM30.17 million a year ago, while revenue also surged from RM385.5 million for the previous year.

However, despite cutting their TPs for Supermax, both research houses raised their earnings forecasts due to higher ASPs seen for the coming quarters.

Kenanga said it likes Supermax for its original brand manufacturing (OBM) model, which enables it to extract higher margins from distributor pieces compared to original equipment manufacturer (OEM) models at lower factory prices.

“[We] raise [our] FY21E/FY22E net profit by 27%/16% after hiking our ASP [assumptions] from US$65/1,000 pieces and US$45/1,000 pieces to US$70/1,000 pieces and US$50/1,000 pieces respectively,” said Choo.

RHB also increased its forecast for FY21 by 36% due to a higher ASP assumption.

“However, we maintain our FY22F-23F earnings as we keep [our] ASP assumptions unchanged. Note that our FY21-23F blended ASPs of US$89, US$57 and US$48 already assume an ASP decline in the future once Covid-19 ends,” said Lim.

In the short term, Lim said RHB expects earnings for Supermax to continue to rise for 3QFY21.

“Beyond that, Supermax is a beneficiary of stable glove growth demand of 8%-10% annually. Our ESG (environmental, social and governance) score for Supermax is 2.89,” added Lim.

Posted by Stockisnotfun > 2021-02-02 20:56 | Report Abuse

What about the variable that supply over Demand?

Posted by Addy > 2021-02-25 22:35 | Report Abuse

Muhyiddin is Malaysia’s first Covid-19 vaccine recipient
https://www.youtube.com/watch?v=zggNvAMs39E